
About Prosetta Biosciences
Prosetta Biosciences is a Healthcare company based in San Francisco (United States) founded in 2003. Antiviral therapeutics are developed via a proprietary drug discovery platform. Prosetta Biosciences has raised $35.14 million across 7 funding rounds from investors including Takeda Pharmaceuticals, HHS and Alger. Its Indian entity Prosetta Bio-Conformatics Private Limited reported revenue of βΉ1.18 Cr. Prosetta Biosciences offers products and services including Small Molecule Therapeutics. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Viral. Its competitors include Moderna, Adaptive Biotechnologies and Novavax; 2 of its 3 listed competitors have raised funding.
Company details
Developer of antiviral and other therapeutics using proprietary drug discovery platform. The companys research is based on its proprietary cell-free protein synthesis or CFPSS drug discovery platform allows for the identification of small molecule drugs, which may be missed by traditional pharma screening methods. The company has successfully produced potent compounds which display activity against multiple strains of many viral families including lead series of molecules that are effective antiviral agents against influenza, HIV, and HCV.
- Headquarters San Francisco, United States
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Website prosetta.com
- Social LinkedIn
- Legal Name Prosetta Bio-Conformatics Private Limited
- Date of Incorporation 03 Mar, 2004
- Jurisdiction Mysore, Karnataka, India
- Indian entity revenue₹1.18 Cr
FY 2024 · -11% YoY
- Indian entity net profit₹10.3 Lakh
FY 2024 · 9% margin
- Indian entity EBITDA₹28.5 Lakh
FY 2024 · 24% margin
- Total Equity Funding$35.14M (USD)
in 7 rounds
- Latest Funding Round$31.1M (USD), Series D
Nov 2015
- InvestorsTakeda Pharmaceuticals
& 3 more
Associated legal entities of Prosetta Biosciences
Prosetta Biosciences operates through Prosetta Bio-Conformatics Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2024) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Prosetta Bio-Conformatics Private Limited CIN U51397KA2004PTC033501 | Active | 03 Mar 2004 | Mysore, Karnataka | ₹1.2 Cr | 4 | View details |
Products & Services of Prosetta Biosciences
Prosetta Biosciences offers a comprehensive portfolio of products and services, including Small Molecule Therapeutics.
Advances novel molecules to modulate protein complexes for disease therapy
Funding Insights of Prosetta Biosciences
Prosetta Biosciences has successfully raised a total of $35.14M across 7 strategic funding rounds. The most recent funding activity was a Series D round of $31.1 million completed in November 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $35.14M
- Total Rounds 7
- Last Round Series D β $31.1M
- First Round $2M
(May 2007)
- Investors Count 4
All 7 funding rounds of Prosetta Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2015 | $31.1M | Series D | β | β | |
| Jul 2012 | $2.04M | Series B | β | β | β |
| Jun 2012 | $441,743 | Grant | β | β | |
| Jun 2012 | $441,743 | Grant | β | β | |
| Apr 2011 | $253,958 | Grant | β | β | |
| May 2010 | $451,580 | Grant | β | β | |
| May 2007 | $2M | Series A | β | β | β |
4 investors in total: 4 institutional.
Investors in Prosetta Biosciences
Prosetta Biosciences has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Takeda Pharmaceuticals, HHS and Alger.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
ESG investments are managed by this venture capital firm. | 1964 | alger.com | New York, United States | |
Takeda Pharmaceuticals is engaged in developing innovative medicines globally. | 1781 | takeda.com | Tokyo, Japan | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Administers health care and support for military personnel and operations. | health.mil | Falls Church, United States |
Investor details for Prosetta Biosciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Prosetta Bio-Conformatics Private Limited (Prosetta Biosciences)
Prosetta Bio-Conformatics Private Limited is the primary company behind Prosetta Biosciences. The board of Prosetta Bio-Conformatics Private Limited currently have 4 directors; the longest-serving is Vishwanath Rao Lingappa, appointed in 2004.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Vishwanath Rao Lingappa DIN 02272426 | Director | 03 Mar 2004 | 22 yrs 8 mo | Prosetta Bio-Conformatics Private Limited |
| Karl Michael Manheim DIN 02234843 | Director | 03 Mar 2004 | 22 yrs 8 mo | Prosetta Bio-Conformatics Private Limited |
| Nisrani Hosmane Ramakrishna DIN 02744329 | Director | 30 Jun 2007 | 19 yrs 4 mo | Prosetta Bio-Conformatics Private Limited |
| Mahadevappa Dharma Prasad DIN 02327449 | Director | 30 Jun 2007 | 19 yrs 4 mo | Prosetta Bio-Conformatics Private Limited |
People of Prosetta Biosciences
8 people are tracked at Prosetta Biosciences (2 in leadership, 6 in board & advisors).
| Name | Role | Group |
|---|---|---|
| CEO & CTO | Leadership | |
Dmitry T. | Director of IT | Leadership |
| Director | Board & advisors | |
David N. Keys | Director | Board & advisors |
Dale Bredesen | Director | Board & advisors |
Charles M. Parrish | Director | Board & advisors |
Hal Liebes | Director | Board & advisors |
Thomas Higgins | Chairman | Board & advisors |
Complete people profiles for Prosetta Biosciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Prosetta Biosciences
Figures of Prosetta Bio-Conformatics Private Limited, the primary company behind Prosetta Biosciences, for FY 2024. Revenue was ₹1.18 Cr (-11% year on year). Net profit was ₹10.3 Lakh (9% margin). EBITDA was ₹28.5 Lakh (24% margin). Revenue has grown at a compounded annual rate of -7% over three years and -8% over five years.
- ₹1.18 CrRevenue · FY 2024 · -11% YoY
- ₹10.3 LakhNet profit · 9% margin
- ₹28.5 LakhEBITDA · 24% margin
- ₹21.8 LakhPaid-up capital
- -7%Revenue CAGR, 3 years
- -8%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Prosetta Bio-Conformatics Private Limited are on its company page.
Detailed financial statements for Prosetta Biosciences
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Prosetta Biosciences
3 dated milestones of Prosetta Biosciences across 12 years, from founding to its latest funding, stage changes and deals.
- Founded Prosetta Biosciences is founded.
- Funding First funding round of $2.0M.
- Funding Latest funding round, Series D, of $31.1M.
Competitors of Prosetta Biosciences
Prosetta Biosciences has 3 listed competitors in our database, 2 of them funded. They include Moderna, Adaptive Biotechnologies and Novavax.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| adaptivebiotech.com | 2009 | Seattle, United States | $419.15M | 609 | Clinical diagnostics and drug discovery for immune diseases are provided. | |
| novavax.com | 1987 | Gaithersburg, United States | 184 | Novel vaccines are developed using nanoparticle and matrix adjuvant technology. |
Detailed competitors of Prosetta Biosciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Prosetta Biosciences
The website of Prosetta Biosciences (prosetta.com) receives about 2.2K visits a month.
- Monthly visits2.2K
▲ 5.9% vs previous month
Top companies in Infectious Diseases
3 companies that operate in the same segment as Prosetta Biosciences (Infectious Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 87.11 M | 4,647 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Prosetta Biosciences
Prosetta Biosciences was founded in 2003 and raised its 1st funding round 4 years after it was founded.
Prosetta Biosciences is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Prosetta Biosciences is a funded company, having raised a total of $35.14M across 7 funding rounds to date. The company's 1st funding round was a Series A of $2M, raised on May 2007.
The primary company behind Prosetta Biosciences, Prosetta Bio-Conformatics Private Limited, reported revenue of βΉ1.18 Cr for FY 2024, down 11% year on year.
Developer of antiviral and other therapeutics using proprietary drug discovery platform. The companys research is based on its proprietary cell-free protein synthesis or CFPSS drug discovery platform allows for the identification of small molecule drugs, which may be missed by traditional pharma screening methods. The company has successfully produced potent compounds which display activity against multiple strains of many viral families including lead series of molecules that are effective antiviral agents against influenza, HIV, and HCV.
Prosetta Biosciences's top competitors include Moderna, Adaptive Biotechnologies and Novavax.
Prosetta Biosciences offers Small Molecule Therapeutics.
Prosetta Biosciences has 4 investors. Key investors include Takeda Pharmaceuticals, HHS, Alger, and Military Health.
Prosetta Biosciences operates through Prosetta Bio-Conformatics Private Limited.
The legal entities of Prosetta Biosciences currently have 4 directors, including Vishwanath Rao Lingappa, Nisrani Hosmane Ramakrishna, Karl Michael Manheim and others.